ATE197404T1 - Einen für tumore cytotoxischen faktor enthaltende pharmazeutische zusammensetzung - Google Patents

Einen für tumore cytotoxischen faktor enthaltende pharmazeutische zusammensetzung

Info

Publication number
ATE197404T1
ATE197404T1 AT94301251T AT94301251T ATE197404T1 AT E197404 T1 ATE197404 T1 AT E197404T1 AT 94301251 T AT94301251 T AT 94301251T AT 94301251 T AT94301251 T AT 94301251T AT E197404 T1 ATE197404 T1 AT E197404T1
Authority
AT
Austria
Prior art keywords
tcf
cytotoxic factor
pharmaceutical composition
tumor cytotoxic
composition containing
Prior art date
Application number
AT94301251T
Other languages
English (en)
Inventor
Hitoshi Hayasaka
Nobuyuki Kawashima
Shimokoyama
Masatsugu Ueda
Eitaro Kumazawa
Original Assignee
Snow Brand Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd
Application granted granted Critical
Publication of ATE197404T1 publication Critical patent/ATE197404T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94301251T 1993-02-23 1994-02-22 Einen für tumore cytotoxischen faktor enthaltende pharmazeutische zusammensetzung ATE197404T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP05782693A JP3552240B2 (ja) 1993-02-23 1993-02-23 高濃度ｔｃｆ製剤

Publications (1)

Publication Number Publication Date
ATE197404T1 true ATE197404T1 (de) 2000-11-11

Family

ID=13066735

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94301251T ATE197404T1 (de) 1993-02-23 1994-02-22 Einen für tumore cytotoxischen faktor enthaltende pharmazeutische zusammensetzung

Country Status (11)

Country Link
US (1) US5510327A (de)
EP (1) EP0612530B1 (de)
JP (1) JP3552240B2 (de)
KR (1) KR100271671B1 (de)
AT (1) ATE197404T1 (de)
AU (1) AU678421B2 (de)
CA (1) CA2116192C (de)
DE (1) DE69426244T2 (de)
DK (1) DK0612530T3 (de)
ES (1) ES2153403T3 (de)
ZA (1) ZA941198B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69330960T2 (de) * 1992-07-16 2002-04-11 Snow Brand Milk Products Co Ltd Normalisierer der blutkoagulation enthaltend tcf-ii als aktiven bestandteil
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
AU4027601A (en) * 1995-07-11 2001-07-26 Snow Brand Milk Products Co., Ltd. Lyophilized HGF preparations
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
US20020041863A1 (en) * 1997-03-14 2002-04-11 Masamichi Kojiro Preventive and/or therapeutic agent for cachexia
EP1180368B1 (de) * 1999-05-31 2007-04-18 Mitsubishi Chemical Corporation Gefriergetrocknete hgf-präparationen
GB9921960D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and amino acids
US7754686B2 (en) * 2000-08-31 2010-07-13 Novartis Vaccines And Diagnostics, Inc. Stabilized FGF formulations containing reducing agents
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
CN105168127A (zh) * 2015-10-23 2015-12-23 广西裕源药业有限公司 一种塑瓶装氯化钠注射液的生产工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076701A (en) * 1975-07-29 1978-02-28 Immunology Research Foundation, Inc. Tumor complement fraction recovery method and product
US4481137A (en) * 1982-02-26 1984-11-06 Mochida Pharmaceutical Co., Ltd. Glycoproteins and processes for their production
JPS60112718A (ja) * 1983-11-21 1985-06-19 Kyorin Pharmaceut Co Ltd 抗腫瘍作用を示す蛋白性物質及びその製造方法
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
JP2750372B2 (ja) * 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
JP2634323B2 (ja) * 1990-07-13 1997-07-23 雪印乳業株式会社 Ｔｃｆ‐▲ｉｉ▼のアミノ酸配列をコードするｄｎａを含むプラスミド，形質転換細胞及びこれを用いて生理活性物質を生産する方法

Also Published As

Publication number Publication date
CA2116192A1 (en) 1994-08-24
ES2153403T3 (es) 2001-03-01
EP0612530A3 (de) 1995-05-10
CA2116192C (en) 2005-05-10
KR100271671B1 (ko) 2000-11-15
DE69426244T2 (de) 2001-03-29
EP0612530A2 (de) 1994-08-31
DE69426244D1 (de) 2000-12-14
EP0612530B1 (de) 2000-11-08
KR950024769A (ko) 1995-09-15
DK0612530T3 (da) 2001-03-05
JP3552240B2 (ja) 2004-08-11
US5510327A (en) 1996-04-23
AU5630794A (en) 1994-09-01
ZA941198B (en) 1994-09-20
AU678421B2 (en) 1997-05-29
JPH06247872A (ja) 1994-09-06

Similar Documents

Publication Publication Date Title
NO911063L (no) 1,4,7,10-tetraazacyklododekanbutyltrioler, fremgangsmaate for fremstilling derav, samt komplekser og preparater som inneholder slike forbindelser.
AU610636B2 (en) Stabilised human protein preparations
ATE197404T1 (de) Einen für tumore cytotoxischen faktor enthaltende pharmazeutische zusammensetzung
BR9714434A (pt) Formulações de interferon liquidas estáveis
HU9301520D0 (en) Methods for producing cyclopeptides promoting absorption of peptides and albumins through mucous membrane as well as pharmaceutical preparations containing said compounds as auxiliary agents
IL83086A (en) Stable,injectable solutions of vincristine salts
NO883520L (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
IL59083A (en) Pharmaceutical composition containing thymidine and a salicyclic acid derivative as a solubilizing agent therefor
DE69114635T2 (de) 1,3-Diphenyl-2-propin-1-one.
EP0063328A3 (de) Sekretin enthaltende Zusammensetzungen und Verfahren zur Verhütung der Adsorption von Sekretin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee